Gossamer Bio Inc (GOSS) - Total Assets
Based on the latest financial reports, Gossamer Bio Inc (GOSS) holds total assets worth $208.82 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Gossamer Bio Inc to assess the company's total reinvestment commitment from operating cash flow.
Gossamer Bio Inc - Total Assets Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's total assets have evolved over time, based on quarterly financial data. Check Gossamer Bio Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Gossamer Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Gossamer Bio Inc's total assets of $208.82 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.6% |
| Accounts Receivable | $5.34 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GOSS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gossamer Bio Inc's current assets represent 98.3% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2024, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Gossamer Bio Inc Competitors by Total Assets
Key competitors of Gossamer Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Gossamer Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.28 | 6.74 | 13.51 |
| Quick Ratio | 3.28 | 6.74 | 13.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $141.87 Million | $293.18 Million | $483.67 Million |
Gossamer Bio Inc - Advanced Valuation Insights
This section examines the relationship between Gossamer Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 1.1% |
| Total Assets | $315.29 Million |
| Market Capitalization | $38.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gossamer Bio Inc's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gossamer Bio Inc's assets grew by 1.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gossamer Bio Inc (2016–2024)
The table below shows the annual total assets of Gossamer Bio Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $315.29 Million | +1.08% |
| 2023-12-31 | $311.92 Million | +14.49% |
| 2022-12-31 | $272.45 Million | -20.72% |
| 2021-12-31 | $343.66 Million | -36.29% |
| 2020-12-31 | $539.43 Million | +26.45% |
| 2019-12-31 | $426.60 Million | +78.18% |
| 2018-12-31 | $239.42 Million | +53702.02% |
| 2017-12-31 | $445.00K | +641.67% |
| 2016-12-31 | $60.00K | -- |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more